Calidi Biotherapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Calidi Biotherapeutics, Inc. (CLDI) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$4.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$4.16M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.12M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$4.06M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$5.18M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$20.05M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$22.19M.
- Calidi Biotherapeutics, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$29.25M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.16M 10-Q · filed 2026-08-13 | -$8.28M 10-Q · filed 2026-08-13 | -$12.34M derived: sum of 3 quarters · filed 2026-08-13 | -$17.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.12M 10-Q · filed 2026-05-14 | -$8.18M derived: sum of 2 quarters · filed 2026-05-14 | -$13.36M derived: sum of 3 quarters · filed 2026-05-14 | -$19.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$9.24M derived: sum of 2 quarters · filed 2026-03-27 | -$14.99M derived: sum of 3 quarters · filed 2026-08-13 | -$20.05M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$5.18M 10-Q · filed 2025-11-13 | -$10.93M derived: sum of 2 quarters · filed 2026-08-13 | -$15.99M 10-Q · filed 2025-11-13 | -$20.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$5.75M 10-Q · filed 2026-08-13 | -$10.81M 10-Q · filed 2026-08-13 | -$14.91M derived: sum of 3 quarters · filed 2026-08-13 | -$20.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$5.06M 10-Q · filed 2026-05-14 | -$9.16M derived: sum of 2 quarters · filed 2026-05-14 | -$14.28M derived: sum of 3 quarters · filed 2026-05-14 | -$20.08M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$9.22M derived: sum of 2 quarters · filed 2026-03-27 | -$15.02M derived: sum of 3 quarters · filed 2026-03-27 | -$22.19M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$5.12M 10-Q · filed 2025-11-13 | -$10.92M derived: sum of 2 quarters · filed 2025-11-13 | -$18.09M 10-Q · filed 2025-11-13 | -$26.36M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$5.80M 10-Q · filed 2025-08-08 | -$12.97M 10-Q · filed 2025-08-08 | -$21.24M derived: sum of 3 quarters · filed 2025-08-08 | -$23.25M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$7.17M 10-Q · filed 2025-05-14 | -$15.44M derived: sum of 2 quarters · filed 2025-05-14 | -$17.45M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$10.28M derived: sum of 2 quarters · filed 2025-03-31 | -$29.25M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$2.01M 10-Q · filed 2024-11-12 | -$20.98M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |